Closed-system manufacturing of therapeutic NK cells using automated cell enrichment and concentration processes enables scalable, robust and cost-effective solutions.

Importantly, CD56 + NK content and product purity, assessed via QC testing before and after harvest, remained stable at over 80%, though we observed a slight trend toward higher yield with larger cell culture volumes.

also in 3,290 other papers